Table 3.

The improvement of skin reaction severity by Film over Cream in different cohorts and subcohorts

	RISRAS scoresa
	Film		Cream
Combined	Researcher	Patient	Combined	Researcher	Patient
China prophylactic (n = 11) % improvement p valueb	2.97 ± 0.37 29% <0.003	1.95 ± 0.30 35% <0.003	1.06 ± 0.16 15% 0.185	4.23 ± 0.35	3.02 ± 0.36	1.30 ± 0.15
NZ both protocols (n = 22) % improvement p value	3.03 ± 0.26 27% <0.001	2.31 ± 0.14 14% 0.001	0.71 ± 0.17 51% <0.001	4.13 ± 0.36	2.68 ± 0.16	1.44 ± 0.26
NZ management (n = 11) % improvement p value	3.23 ± 0.41 25% 0.005	2.41 ± 0.25 15% 0.019	0.81 ± 0.21 46% 0.005	4.32 ± 0.48	2.81 ± 0.28	1.50 ± 0.26
NZ prophylactic (n = 11) % improvement p value	2.62 ± 0.35 29% 0.008	2.11 ± 0.11 12% 0.022	0.51 ± 0.27 60% 0.008	3.68 ± 0.56	2.41 ± 0.15	1.26 ± 0.48
NZ RT only (n = 8) % improvement p value	2.62 ± 0.12 30% 0.012	2.15 ± 0.27 14% 0.018	0.45 ± 0.14 63% 0.012	3.73 ± 0.46	2.50 ± 0.24	1.22 ± 0.25
NZ chemoRT (n = 14) % improvement p value	3.10 ± 0.43 25% 0.004	2.15 ± 0.21 13% 0.028	1.09 ± 0.29 47% 0.003	4.15 ± 0.59	2.67 ± 0.25	1.47 ± 0.45
NZ IMRT (n = 11) % improvement p value	3.53 ± 0.47 30% 0.003	2.38 ± 0.26 17% 0.003	1.16 ± 0.27 51% 0.003	5.05 ± 0.57	2.86 ± 0.29	2.18 ± 0.40
NZ VMAT (n = 11) % improvement p value	2.62 ± 0.35 25% 0.008	2.11 ± 0.11 11% 0.022	0.51 ± 0.27 58% 0.008	3.86 ± 0.56	2.41 ± 0.56	1.26 ± 0.48
NZ females (n = 5) % improvement p value	2.37 ± 0.33 44% 0.043	1.78 ± 0.17 24% 0.043	0.55 ± 0.18 71% 0.043	4.25 ± 0.59	2.34 ± 0.13	1.91 ± 0.58
NZ males (n = 17) % improvement p value	3.09 ± 0.33 21% 0.001	2.40 ± 0.16 11% 0.012	0.69 ± 0.21 44% 0.001	3.93 ± 0.44	2.69 ± 0.20	1.22 ± 0.29

^aValues are averages ± SEM.

^bWilcoxon signed-rank test for differences in skin reaction severity between Film and Cream.